AACR 2020 – Gracell validates a novel Car-T target
The Chinese group sees responses in all five subjects treated with its allogeneic anti-CD7 Car-T therapy.
AACR 2020 preview – no Tigit, but plenty of novel mechanisms
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
